US Stock MarketDetailed Quotes

NARI Inari Medical(Delisted)

Watchlist
  • 79.970
  • 0.0000.00%
Close Feb 18 16:00 ET
4.68BMarket Cap-59.24P/E (TTM)

About Inari Medical(Delisted) Company

Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Company Profile

SymbolNARI
Company NameInari Medical(Delisted)
Issue Price19.00
CEOMr. Andrew Hykes
MarketNASDAQ
Employees1300
Fiscal Year Ends12-31

Company Executives

  • Name
  • Position
  • Salary
  • Andrew Hykes
  • Director, President and Chief Executive Officer
  • 5.08M
  • Kevin Strange
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. Thomas Tu, M.D.
  • Chief Medical Officer
  • 2.50M
  • Donald Milder
  • Chairman of the Board
  • 266.43K
  • William Hoffman
  • Director
  • 198.43K
  • Rebecca Chambers
  • Independent Director
  • 220.93K
  • Catherine M. Szyman
  • Independent Director
  • 220.47K
  • Dr. Jonathan D. Root,M.D.
  • Independent Director
  • 230.93K
  • Robert Warner
  • Independent Director
  • 220.93K
  • Dana G. Mead, Jr
  • Independent Director
  • 218.43K
  • Cynthia L. Lucchese
  • Independent Director
  • 235.93K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More